See more : Videolocity International, Inc. (VCTY) Income Statement Analysis – Financial Results
Complete financial analysis of BioXcel Therapeutics, Inc. (BTAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioXcel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- AerSale Corporation (ASLE) Income Statement Analysis – Financial Results
- Columbia Sportswear Company (COLM) Income Statement Analysis – Financial Results
- McPhy Energy S.A. (MPHYF) Income Statement Analysis – Financial Results
- Dianguang Explosion-proof Technology Co., Ltd. (002730.SZ) Income Statement Analysis – Financial Results
- Yamax Corp. (5285.T) Income Statement Analysis – Financial Results
BioXcel Therapeutics, Inc. (BTAI)
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38M | 375.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 20.00K | 297.00K | 188.00K | 156.00K | 17.00K | 1.00K | 0.00 | 0.00 |
| Gross Profit | 120.00K | 355.00K | -297.00K | -188.00K | -156.00K | -17.00K | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 8.70% | 94.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 84.33M | 91.24M | 52.71M | 58.00M | 25.80M | 14.56M | 2.69M | 1.40M | 233.00K |
| General & Administrative | 63.51M | 68.76M | 54.23M | 24.30M | 7.80M | 5.40M | 1.85M | 721.00K | 0.00 |
| Selling & Marketing | 19.90M | 13.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 83.41M | 68.76M | 54.23M | 24.30M | 7.80M | 5.40M | 1.85M | 721.00K | 403.00K |
| Other Expenses | 4.16M | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 171.90M | 160.00M | 106.94M | 82.30M | 33.60M | 19.96M | 4.54M | 2.12M | 636.00K |
| Cost & Expenses | 173.16M | 160.02M | 106.94M | 82.30M | 33.60M | 19.96M | 4.54M | 2.12M | 636.00K |
| Interest Income | 5.65M | 2.53M | 4.00K | 155.00K | 633.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.31M | 8.21M | 40.00K | 27.00K | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 318.00K | 327.00K | 297.00K | 188.00K | 156.00K | 17.00K | 1.00K | 2.12M | 0.00 |
| EBITDA | -165.42M | -157.38M | -107.00M | -81.98M | -32.81M | -19.25M | -4.54M | 0.00 | -636.00K |
| EBITDA Ratio | -11,987.03% | -42,011.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -171.78M | -159.65M | -106.94M | -82.30M | -33.60M | -19.96M | -4.54M | -2.12M | -636.00K |
| Operating Income Ratio | -12,447.97% | -42,572.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.27M | -6.11M | -358.00K | 128.00K | 633.00K | 692.00K | -2.00K | 0.00 | 0.00 |
| Income Before Tax | -179.05M | -165.76M | -106.93M | -82.17M | -32.97M | -19.27M | -4.54M | -2.12M | -636.00K |
| Income Before Tax Ratio | -12,974.86% | -44,201.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 6.09M | -301.00K | -161.00K | -633.00K | 692.00K | 0.00 | -2.12M | 0.00 |
| Net Income | -179.05M | -171.85M | -106.63M | -82.01M | -32.34M | -19.27M | -4.54M | -2.12M | -636.00K |
| Net Income Ratio | -12,974.86% | -45,826.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.30 | -0.14 | -0.04 |
| EPS Diluted | -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.30 | -0.14 | -0.04 |
| Weighted Avg Shares Out | 29.13M | 28.02M | 26.37M | 21.68M | 16.29M | 14.57M | 15.19M | 15.65M | 15.94M |
| Weighted Avg Shares Out (Dil) | 29.13M | 28.02M | 26.37M | 21.68M | 16.29M | 14.57M | 15.19M | 15.65M | 15.94M |
BioXcel Therapeutics shares pop after audit of Alzheimer's trial data
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
Why Shares of BioXcel Therapeutics Fell This Week
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit
Source: https://incomestatements.info
Category: Stock Reports